Document Detail


L-carnitine reduces doxorubicin-induced apoptosis through a prostacyclin-mediated pathway in neonatal rat cardiomyocytes.
MedLine Citation:
PMID:  19552975     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: Clinical use of doxorubicin is greatly limited by its severe cardiotoxic side effects. L-carnitine is a vitamin-like substance which has been successfully used in many cardiomyopathies, however, the intracellular mechanism(s) remain unclear. The objective of this study was set to evaluate the protective effect of L-carnitine on doxorubicin-induced cardiomyocyte apoptosis, and to explore its intracellular mechanism(s).
METHODS: Primary cultured neonatal rat cardiomyocytes were treated with doxorubicin (1 µM) with or without pretreatment with L-carnitine (1-30 mM). Lactate dehydrogenase assay, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling staining, and flow cytometry measurement were used to assess cytotoxicity and apoptosis. Fluorescent probes 2',7'-dichlorofluorescein diacetate and chemiluminescence assay of superoxide production were used to detect the production of reactive oxygen species. Western blotting was used to evaluate the quantity of cleaved caspase-3, cytosol cytochrome c, and Bcl-x(L) expression.
RESULTS: L-carnitine inhibited doxorubicin-induced reactive oxygen species generation and NADPH oxidase activation, reduced the quantity of cleaved caspase-3 and cytosol cytochrome c, and increased Bcl-x(L) expression, resulting in protecting cardiomyocytes from doxorubicin-induced apoptosis. In addition, L-carnitine was found to increase the prostacyclin (PGI(2)) generation in cardiomyocytes. The siRNA transfection for PGI(2) synthase significantly reduced L-carnitine-induced PGI(2) and L-carnitine's protective effect. Furthermore, blockade the potential PGI(2) receptors, including PGI(2) receptors (IP receptors), and peroxisome proliferator-activated receptors alpha and delta (PPARα and PPARδ), revealed that the siRNA-mediated blockage of PPARα considerably reduced the anti-apoptotic effect of L-carnitine.
CONCLUSIONS: These findings suggest that L-carnitine protects cardiomyocytes from doxorubicin-induced apoptosis in part through PGI(2) and PPARα-signaling pathways, which may potentially protect the heart from the severe toxicity of doxorubicin.
Authors:
Hung-Hsin Chao; Ju-Chi Liu; Hong-Jye Hong; Jia-Wei Lin; Cheng-Hsien Chen; Tzu-Hurng Cheng
Related Documents :
17547755 - Testicular involution prior to sex change in gilthead seabream is characterized by a de...
11880545 - Detection of 1cen--1q12 lesions in different phases of the cell cycle: dual colour fish...
19765465 - Apoptosis and proliferation of cardiomyocytes and interstitial mononuclear cells: assoc...
9603995 - Induction of apoptosis by phosphatidylserine.
8379295 - Scavenger macrophages and central macrophages of erythroblastic islands in liver hemopo...
1337425 - Vitamin d3 and skin diseases.
Publication Detail:
Type:  Journal Article     Date:  2009-06-23
Journal Detail:
Title:  International journal of cardiology     Volume:  146     ISSN:  1874-1754     ISO Abbreviation:  Int. J. Cardiol.     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-01-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8200291     Medline TA:  Int J Cardiol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  145-52     Citation Subset:  IM    
Copyright Information:
Copyright © 2009 Elsevier Ireland Ltd. All rights reserved.
Affiliation:
Department of Medicine, Taipei Medical University, Taipei, Taiwan, ROC; Department of Cardiac Surgery, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan, ROC.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Acute worsening in migraine symptoms following PFO closure: a matter of fact?
Next Document:  Usefulness of a 0.010-inch guidewire compatible balloon for crossing stent-jailed sidebranches.